Tumor Clearance and Immune Cell Recruitment in UV-Induced Murine Squamous Cell Carcinoma Exposed to Ablative Fractional Laser and Imiquimod Treatment.
ablative fractional laser
imiquimod
immune cell recruitment
keratinocyte carcinoma
squamous cell carcinoma
Journal
Lasers in surgery and medicine
ISSN: 1096-9101
Titre abrégé: Lasers Surg Med
Pays: United States
ID NLM: 8007168
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
23
02
2021
received:
13
11
2020
pubmed:
4
4
2021
medline:
28
1
2022
entrez:
3
4
2021
Statut:
ppublish
Résumé
Keratinocyte carcinoma (KC) is the most common cancer worldwide, and squamous cell carcinoma (SCC) is the second most frequent subtype. Ablative fractional laser (AFL)-assisted drug delivery significantly enhances the uptake of topically applied drugs. The objective of this study was to assess tumor response and perform a descriptive characterization of the local recruitment of immune cells and systemic immune mediator levels in an ultraviolet radiation (UVR)-induced murine SCC model after AFL treatment alone and combined with topical imiquimod. Immunocompetent hairless mice (C3·Cg/TifBomTac, n = 74) were irradiated with solar-simulated UVR until 3-mm SCCs developed. The mice were divided into four interventional groups: AFL alone, AFL + imiquimod, imiquimod alone, and untreated SCC controls. AFL was given as a single treatment, whereas imiquimod was applied daily until the mice were euthanized on Days 0, 2, 7, or 14. SCCs were photographed and measured (mm) to assess the therapeutic response. Skin samples were processed for histopathological and immunohistochemical analyses, as well as for flow cytometry. Cytokine expression changes in sera were analyzed using ELISpot cytokine arrays. Treatment of mouse SCCs with AFL + imiquimod induced the most robust immune cell infiltration and the greatest proportion of tumor clearance compared to other interventions. Early innate immune cell infiltration was induced by AFL + imiquimod treatment as the number of neutrophils and macrophages had increased fourfold within 2 days of treatment initiation compared with untreated SCC control mice (P < 0.05). AFL treatment alone had a more limited effect, with a fourfold increase in neutrophils (P < 0.05) but no significant increase in the number of macrophages. Correspondingly, treatment with AFL + imiquimod had the greatest effects on the adaptive immune cell recruitment: CD4 AFL treatment alone and in combination with imiquimod induces substantial tumor clearance associated with local recruitment of innate and adaptive immune cells in UVR-induced murine SCCs. These results may provide a basis for new immunotherapeutic approaches to KC treatment.
Sections du résumé
BACKGROUND AND OBJECTIVES
Keratinocyte carcinoma (KC) is the most common cancer worldwide, and squamous cell carcinoma (SCC) is the second most frequent subtype. Ablative fractional laser (AFL)-assisted drug delivery significantly enhances the uptake of topically applied drugs. The objective of this study was to assess tumor response and perform a descriptive characterization of the local recruitment of immune cells and systemic immune mediator levels in an ultraviolet radiation (UVR)-induced murine SCC model after AFL treatment alone and combined with topical imiquimod.
STUDY DESIGN/MATERIALS AND METHODS
Immunocompetent hairless mice (C3·Cg/TifBomTac, n = 74) were irradiated with solar-simulated UVR until 3-mm SCCs developed. The mice were divided into four interventional groups: AFL alone, AFL + imiquimod, imiquimod alone, and untreated SCC controls. AFL was given as a single treatment, whereas imiquimod was applied daily until the mice were euthanized on Days 0, 2, 7, or 14. SCCs were photographed and measured (mm) to assess the therapeutic response. Skin samples were processed for histopathological and immunohistochemical analyses, as well as for flow cytometry. Cytokine expression changes in sera were analyzed using ELISpot cytokine arrays.
RESULTS
Treatment of mouse SCCs with AFL + imiquimod induced the most robust immune cell infiltration and the greatest proportion of tumor clearance compared to other interventions. Early innate immune cell infiltration was induced by AFL + imiquimod treatment as the number of neutrophils and macrophages had increased fourfold within 2 days of treatment initiation compared with untreated SCC control mice (P < 0.05). AFL treatment alone had a more limited effect, with a fourfold increase in neutrophils (P < 0.05) but no significant increase in the number of macrophages. Correspondingly, treatment with AFL + imiquimod had the greatest effects on the adaptive immune cell recruitment: CD4
CONCLUSION
AFL treatment alone and in combination with imiquimod induces substantial tumor clearance associated with local recruitment of innate and adaptive immune cells in UVR-induced murine SCCs. These results may provide a basis for new immunotherapeutic approaches to KC treatment.
Substances chimiques
Imiquimod
P1QW714R7M
Types de publication
Case Reports
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1227-1237Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Leiter U, Eigentler T, Garbe C. Epidemiology of skin cancer. Adv Exp Med Biol 2014;810:120-140. https://doi.org/10.1007/978-1-4939-0437-2_7
Wu W, Weinstock MA. Trends of keratinocyte carcinoma mortality rates in the United States as reported on death certificates, 1999 through 2010. Dermatol Surg 2014;40:1395-1401. https://doi.org/10.1097/DSS.0000000000000194
Gualdi G, Monari P, Apalla Z, Lallas A. Surgical treatment of basal cell carcinoma and squamous cell carcinoma. G Ital Dermatol Venereol 2015;150:435-447.
Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-489. https://doi.org/10.1038/nature10673
Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013;14:1014-1022. https://doi.org/10.1038/ni.2703
Corrales L, Matson V, Flood B, Spranger S, Gajewski TF. Innate immune signaling and regulation in cancer immunotherapy. Cell Res 2017;27:96-108. https://doi.org/10.1038/cr.2016.149
Jayaraman SS, Rayhan DJ, Hazany S, Kolodney MS. Mutational landscape of basal cell carcinomas by whole-exome sequencing. J Invest Dermatol 2014;134:213-220. https://doi.org/10.1038/jid.2013.276
Walter A, Barysch MJ, Behnke S, et al. Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas. Clin Cancer Res 2010;16:3562-3570. https://doi.org/10.1158/1078-0432.CCR-09-3136
Omland SH, Nielsen PS, Gjerdrum LM, Gniadecki R. Immunosuppressive environment in basal cell carcinoma: The role of regulatory T cells. Acta Derm Venereol 2016;96:917-921. https://doi.org/10.2340/00015555-2440
Xia A, Zhang Y, Xu J, Yin T, Lu XJ. T Cell Dysfunction in Cancer Immunity and Immunotherapy. Front Immunol 2019;10:1719. https://doi.org/10.3389/fimmu.2019.01719
Schmitt L, Huth S, Amann PM, et al. Direct biological effects of fractional ultrapulsed CO2 laser irradiation on keratinocytes and fibroblasts in human organotypic full-thickness 3D skin models. Lasers Med Sci 2018;33:765-772. https://doi.org/10.1007/s10103-017-2409-1
Soleymani T, Abrouk M, Kelly KM. An analysis of laser therapy for the treatment of nonmelanoma skin cancer. Dermatol Surg 2017;43:615-624. https://doi.org/10.1097/DSS.0000000000001048
Kawakubo M, Cunningham TJ, Demehri S, Manstein D. Fractional laser releases tumor-associated antigens in poorly immunogenic tumor and induces systemic immunity. Sci Rep 2017;7:12751. https://doi.org/10.1038/s41598-017-13095-8
Kawakubo M, Demehri S, Manstein D. Fractional laser exposure induces neutrophil infiltration (N1 phenotype) into the tumor and stimulates systemic anti-tumor immune response. PLOS One 2017;12:e0184852. https://doi.org/10.1371/journal.pone.0184852
Haedersdal M, Erlendsson AM, Paasch U, Anderson RR. Translational medicine in the field of ablative fractional laser (AFXL)-assisted drug delivery: A critical review from basics to current clinical status. J Am Acad Dermatol 2016;74:981-1004. https://doi.org/10.1016/j.jaad.2015.12.008
Wenande E, Olesen UH, Boesen MR, et al. Laser-assisted delivery enhances topical uptake of the anticancer agent cisplatin. Drug Deliv 2018;25:1877-1885. https://doi.org/10.1080/10717544.2018.1534896
Olesen UH, Clergeaud G, Lerche CM, Andresen TL, Haedersdal M. Topical delivery of vismodegib using ablative fractional laser and micro-emulsion formulation in vitro. Lasers Surg Med 2019;51:79-87. https://doi.org/10.1002/lsm.23013
Wenande E, Olesen UH, Nielsen MMB, et al. Fractional laser-assisted topical delivery leads to enhanced, accelerated and deeper cutaneous 5-fluorouracil uptake. Expert Opin Drug Deliv 2017;14:307-317. https://doi.org/10.1080/17425247.2017.1260119
Hendel KK, Bagger C, Olesen UH, et al. Fractional laser-assisted topical delivery of bleomycin quantified by LC-MS and visualized by MALDI mass spectrometry imaging. Drug Deliv 2019;26:244-251. https://doi.org/10.1080/10717544.2019.1574937
Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000;43:S6-S11. https://doi.org/10.1067/mjd.2000.107808
Patel GK, Goodwin R, Chawla M, et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen′s disease): A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2006;54:1025-1032. https://doi.org/10.1016/j.jaad.2006.01.055
Schon MP, Schon M. Imiquimod: Mode of action. Br J Dermatol 2007;157(Suppl 2):8-13. https://doi.org/10.1111/j.1365-2133.2007.08265.x
Luo M, Shi L, Zhang F, et al. Laser immunotherapy for cutaneous squamous cell carcinoma with optimal thermal effects to enhance tumour immunogenicity. Int J Hyperthermia 2018;34:1337-1350. https://doi.org/10.1080/02656736.2018.1446221
Lerche CM, Sepehri M, Serup J, Poulsen T, Wulf HC. Black tattoos protect against UVR-induced skin cancer in mice. Photodermatol Photoimmunol Photomed 2015;31:261-268. https://doi.org/10.1111/phpp.12181
Lerche CM, Togsverd-Bo K, Philipsen PA, Wulf HC. Impact of UVR exposure pattern on squamous cell carcinoma-A dose-delivery and dose-response study in pigmented hairless mice. Int J Mol Sci 2017;18:2738. https://doi.org/10.3390/ijms18122738
Fontenete S, Perez-Moreno M. Isolation of cancer stem cells from squamous cell carcinoma. Methods Mol Biol 2019;1879:407-414. https://doi.org/10.1007/7651_2018_162
Li J, Tan J, Martino MM, Lui KO. Regulatory T-cells: Potential regulator of tissue repair and regeneration. Front Immunol 2018;9:585. https://doi.org/10.3389/fimmu.2018.00585
Nagasawa T. CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4. J Mol Med (Berl) 2014;92:433-439. https://doi.org/10.1007/s00109-014-1123-8
Forbes PD. Relevance of animal models of photocarcinogenesis to humans. Photochem Photobiol 1996;63:357-362. https://doi.org/10.1111/j.1751-1097.1996.tb03041.x
Simons BW, Brayton C. Challenges and limitations of mouse xenograft models of cancer. In: Tinkey P, Uthamanthil R, editors. Patient Derived Tumor Xenograft Models. Cambridge, MA: Elsevier; 2017. pp 25-36.
Manstein D, Herron GS, Sink RK, Tanner H, Anderson RR. Fractional photothermolysis: A new concept for cutaneous remodeling using microscopic patterns of thermal injury. Lasers Surg Med 2004;34:426-438. https://doi.org/10.1002/lsm.20048
Togsverd-Bo K, Lei U, Erlendsson AM, et al. Combination of ablative fractional laser and daylight-mediated photodynamic therapy for actinic keratosis in organ transplant recipients - a randomized controlled trial. Br J Dermatol 2015;172:467-474. https://doi.org/10.1111/bjd.13222
Helsing P, Togsverd-Bo K, Veierod MB, Mork G, Haedersdal M. Intensified fractional CO2 laser-assisted photodynamic therapy vs. laser alone for organ transplant recipients with multiple actinic keratoses and wart-like lesions: A randomized half-side comparative trial on dorsal hands. Br J Dermatol 2013;169:1087-1092. https://doi.org/10.1111/bjd.12507
Wu F. Heat-based tumor ablation: Role of the immune response. Adv Exp Med Biol 2016;880:131-153. https://doi.org/10.1007/978-3-319-22536-4_8
Robustelli Test E, Fumo G, Corbeddu M, Ferreli C, Rongioletti F. Efficacy of Imiquimod 3.75% for the treatment of extensive Bowen′s disease of the face in an elderly patient. Dermatol Ther 2020;33:e13263. https://doi.org/10.1111/dth.13263
Singh M, Singh H, Kakkar N, Zadeng Z, Gupta P. Treatment of squamous cell carcinoma of the eyelid with imiquimod 5% cream. Can J Ophthalmol 2019;54:e24-e27. https://doi.org/10.1016/j.jcjo.2018.03.010
Rosenberg AR, Tabacchi M, Ngo KH, et al. Skin cancer precursor immunotherapy for squamous cell carcinoma prevention. JCI Insight 2019;4. https://doi.org/10.1172/jci.insight.125476
Lee A, Duggan S, Deeks ED. Cemiplimab: A review in advanced cutaneous squamous cell carcinoma. Drugs 2020;80:813-819. https://doi.org/10.1007/s40265-020-01302-2